Cooperative Agreement UG3DA063353
Award Date 9/15/25
Completion Date 8/31/27
Dollars Obligated $1.2M
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Virginia, USA
Similar Awards
- This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $931,338 to Virginia Commonwealth University (VCU) to conduct a mechanistic study on the role of the orexin system and insomnia within a buprenorphine opioid use disorder (OUD) treatment sample. The study aims to investigate how the orexin system and insomnia engage neurobiological mechanisms in individuals with OUD, with the goal of identifying...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $465,750 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Virginia Commonwealth University (VCU). The award will fund research to develop novel mu opioid receptor (MOR) modulators to counteract the effects of synthetic opioids, which are fueling the opioid crisis in the United States. Specifically, the project will design, synthesize, and characterize a...
- This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is funding the development of a novel epigenetic regulator as a potential treatment for opioid use disorder (OUD). The grantee, Epivario Inc., a for-profit biotechnology research organization, will screen a new class of ACSS2 inhibitors and evaluate their efficacy in preclinical animal models of OUD. Specifically, the $275,253 award will support...
- This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), part of the Drug Use and Addiction Research Programs (CFDA 93.279), is supporting Mebias Discovery Inc. in the development of a new chemical entity, MEB-1170, for the treatment of opioid use disorder (OUD). The project will complete preclinical studies in rodents and non-human primates to evaluate the efficacy of MEB-1170 as a maintenance medication for OUD, as well as conduct Phase 1 clinical trials to assess the...
- This Cooperative Agreement, awarded by the National Institute on Drug Abuse (NIDA) under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,664,000.00 in funding to The Washington University to develop negative allosteric modulators (NAMs) of the mu opioid receptor as potential treatments for opioid overdose and opioid use disorder. The key products and services to be delivered through this 2-year award, which runs from September 1, 2025 to August 31, 2027, include...
- This federal Project Grant award of $798,828.00 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to discover novel small molecule therapeutics for the safe and effective treatment of opioid use disorder (OUD). The key products and services to be delivered include: The development of an AI platform called M3.AI that will integrate target-based and phenotype-based methodologies to efficiently identify new drug candidates for OUD...
- This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is for a $1,837,542 project titled "Targeting Treatment-Resistant OUD with Ketamine-Assisted Mindfulness-Oriented Recovery Enhancement." The project aims to investigate the safety, preliminary efficacy, and psycho-physiological mechanisms of combining the psychotherapy Mindfulness-Oriented Recovery Enhancement (MORE) with ketamine...
- This Project Grant award of $398,137 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is for developing high-precision epigenetic therapeutics to address the growing opioid use disorder (OUD) epidemic in the United States. The award will enable Boston Interactome LLC to apply a novel approach targeting protein-protein interactions of the neuronal G9A complex, a key regulator of DFosB expression under chronic opioid exposure....
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, awarded a $2,923,842 Cooperative Agreement under the Drug Use and Addiction Research Programs (CFDA 93.279) to Atai Therapeutics, Inc. (UEI: TE66JYGMACX5) on August 15, 2025. The funding supports the optimization and development of non-hallucinogenic 5-HT2A/2C agonists as potential therapeutics for opioid use disorder (OUD). The project aims to leverage the therapeutic potential of psychedelics while...
- This federal Cooperative Agreement award of $680,100 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is intended to investigate the use of a combined transcranial direct current stimulation (tDCS) and cognitive training intervention as an adjunct treatment for individuals with opioid use disorder (OUD) who are receiving buprenorphine maintenance treatment. The key products and services to be delivered under this award include:...